Lactose derivatives are inhibitors of Trypanosoma cruzi trans-sialidase activity toward conventional substrates in vitro and in vivo

Mostrar todas las versiones(3)

Chagas' disease, caused by Trypanosoma cruzi, affects about 18 million people in Latin America, and no effective treatment is available to date. To acquire sialic acid from the host glycoconjugates, T. cruzi expresses an unusual surface sialidase with trans-sialidase activity (TcTS) that transf...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Agustí, R., París, G., Ratier, L., Frasch, A.C.C., de Lederkremer, R.M.
Formato: JOUR
Materias:
Alternative substrates
HPAEC
Inhibitors
Trans-sialidase
Trypanosoma cruzi
3 o beta dextro galactopyranosylarabinitol
3 o beta dextro galactopyranosylarabinofuranone
3 o beta dextro galactopyranosylarabinopyranose
5 (3' o beta dextro galactopyranosylglucopentitol 1' yl)tetrazole
aminosugar
carbohydrate derivative
enzyme inhibitor
lactitol
lactobionic acid
lactose
lactose derivative
n acetyllactosamine
sialidase
unclassified drug
alkalinity
amperometry
anion exchange chromatography
article
binding site
carbohydrate analysis
concentration response
controlled study
drug efficacy
drug structure
enzyme activity
enzyme inhibition
enzyme specificity
enzyme substrate
human
human cell
in vitro study
in vivo study
parasite virulence
priority journal
Vero cell
Animals
Binding Sites
Cercopithecus aethiops
Chagas Disease
Enzyme Inhibitors
Glycoproteins
Neuraminidase
Protein Binding
Protein Structure, Tertiary
Sialic Acids
Substrate Specificity
Sugar Alcohols
Vero Cells
Virulence
Mammalia
Trypanosoma
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_09596658_v14_n7_p659_Agusti
Aporte de:
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

Ejemplares similares

Ejemplares similares